



Association of Interleukin 13/+110 Gene Polymorphism with Hepatitis B Virus Infection in Golestan Province, Northern Iran

Maryam Zangi^{#1}, Azam Bakhshandeh^{#1}, Masoumeh Mehrpouya¹ and Majid Shahbazi^{1,2,*}

¹Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran

²Aryatinagene Biopharmaceutical Company, Gorgan, Iran

* Corresponding author: Medical Cellular and Molecular Research Center, Golestan University of Medical Sciences, Gorgan, Iran. Tel: +98-1732430353, Email: shahbazimajid@yahoo.co.uk

These authors are contributed equally as the first author.

Received 2018 March 04; Revised 2019 February 18; Accepted 2019 February 24.

Abstract

Background: The most common primary cause of liver cancer is hepatocellular carcinoma (HCC). Cytokines as mediators have significant roles in immune and inflammatory responses. Interleukin-13 (IL-13) is a potent pleiotropic cytokine.

Objectives: The aim of this study was to evaluate the association of IL-13/+110 gene polymorphism in patients with chronic hepatitis B virus (HBV), one of the most important factors that lead to the development of HCC.

Methods: DNA was extracted from peripheral blood cells of all 585 participants including 302 unrelated Hepatitis B surface antigen (HBsAg) positives and 283 healthy matched groups. The IL-13 gene polymorphism (+110 A or G) was genotyped by SSP-PCR method and then genotype frequencies were checked by using the Pearson's chi-square test and/or Fisher exact test.

Results: The frequencies of A/G genotype (CI = 1.18 - 2.34, OR = 1.66, P = 0.004) and A/A genotype (CI = 0.95 - 3.53, OR = 1.84, P = 0.071) were higher in the patients. Also, the frequency of A allele was remarkably higher in the HBV patients than control group (CI = 1.09 - 1.79, OR = 1.84, P = 0.071).

Conclusions: High frequency of A allele in patients rather than control group suggested that A allele probably plays a role in augmenting susceptibility to HBV infection risk and high frequency of G allele in controls suggested this allele has a protective role in this disease.

Keywords: Hepatitis B Virus (HBV), Hepatocellular Carcinoma (HCC), Interleukin-13, Polymerase Chain Reaction (PCR), Polymorphism

1. Background

Amongst hepatitis viruses, hepatitis B virus (HBV), the prototype member of a family of *Hepadnaviridae* (1), can cause lifelong infection with a worldwide distribution and is endemic in many populations (2-4). Infection with HBV can lead to a wide range of diseases such as chronic hepatitis, acute hepatitis, asymptomatic HBV carriers, liver cirrhosis and primary hepatocellular carcinoma (HCC) (5-9). The outstanding causes that lead to the development of HCC, the most common type of liver cancer, are hepatitis C virus (HCV) and HBV (5). A study in the south of Iran illustrated that the main factor for HCC was hepatitis B (6). Hepatitis B virus infection is an important public health problem, mostly leading to significant morbidity and mortality in developing countries (7).

Chronic hepatitis B infection is most commonly found in Asia, the Middle East or Africa (8). Although the prevalence of chronic hepatitis in the United States is 25%, HBV is

responsible for up to 70% - 80% of chronic hepatitis in Iran, suggesting that HBV infection alone is the outstanding cause of chronic liver disease in Iran (7, 9). Iran is located on the intermediate endemic region for hepatitis B infection and outbreak of HBsAg positivity amongst the general adult population which is approximately 3 to 10 percent in various regions (10, 11). Hepatitis B virus chronic infection is determined by persistence of HBsAg in the plasma for at least 6 months (2, 12). The average time for the diagnosis of HBsAg is 30 days (range: 6 to 60 days) (13, 14). Different factors are involved in the clinical courses HBV infection, including viral factors, immunological factors, genetic host factors and environmental factors (2, 15, 16). Host genetic background is recognized as a considerable factor in patients' susceptibility to viral hepatitis (11). The natural outcome in HBV infection differs significantly among individuals, so the gene polymorphisms likely determine the outcome of the infection (17).

Several pathways of the cellular immune system during HBV infection are activated including MAPKs, p53, Sex steroid, Wnt/ β -catenin, TGF, PI3K/AKT, IKK/NF- κ B, Hedgehog and cytokines (4). The understanding of the bases of virus-host interaction necessarily requires expert knowledge of the disease's immunopathogenesis and its cytokine secretion pattern, as well as the importance of the immunological profile of the host (18, 19).

Interleukin-13, a type 2 T cell helper (TH2), is a pleiotropic cytokine and important regulator of inflammatory immune responses (20-22). IL-13 is a single-chain glycosylated polypeptide that belongs to the IL-13/IL-4 family. IL-13 inhibits production of pro-inflammatory cytokines and chemokines and also down-regulates macrophage activity. Its protein and antibody are more as an important mediator of immunoregulatory processes in various cell types (20, 23). Interleukin-13 is activated in response to the inflammatory diseases. Association of genetic polymorphisms in IL-13 and its receptor component proteins have been verified to be affiliated with higher disease prevalence rates (24).

2. Objectives

This case-control study was designed to evaluate the association of IL-13 gene polymorphisms and the risk of HBV infection. This case-control study was designed to evaluate the effects of TNF- α (-308G > A) and TNF- α (-238G > A) on mRNA expression level and risk of coronary artery disease.

3. Methods

3.1. Subjects

In this study, the blood samples were collected from 585 Iranian subjects including Hepatitis B surface antigen (HBS-Ag) positive individuals who referred to Medical Cellular & Molecular Research Center (MCMRC) of Taleghani Hospital (Gorgan; northeast of Iran) and 283 healthy controls who were recruited from the Golestan Blood Transfusion Organization. The healthy subjects without the history of autoimmune or inflammatory diseases were also matched for age, sex and ethnic origin as HBS-Ag positive cases. According to McDonald's criteria (25) and based on clinical and paraclinical findings, infectious disease specialists diagnosed HBS-Ag positive cases.

3.2. Nucleic Acid Extraction and Genotyping

DNA was extracted from the whole blood using a modified standard protocol (26). Therefore, red blood cells were lysed in lysis buffer and then SDS (10%), EDTA and 10 μ l proteinase K were added to the remaining white cells. By

sequence-specific primer-polymerase chain reaction (SSP-PCR) method (27), IL-13 gene polymorphism (+ 110 A or G) was genotyped. Details of used primer sequences and fragment size are presented in Table 1. Each PCR reaction contained 100 -150 ng of genomic DNA, 9.5 ml master mix containing 20 mM dNTP, 1X Ready load PCR buffer, 12% Sucrose (Merck, Germany), 1U Taq DNA polymerase (GenetBio, Korea), 6 mM human growth hormone (HGH) primer as an internal control, and 30 mM of each specific IL-13 primer.

Table 1. PCR Primer Sequences for IL-13 (+ 110)

Gene	Annealing Temperature	Fragment Primers Size	Sequences
IL-13	60	204 bp	F (G):5'-ACTTTTTCGCGAGGGACG-3'
			F (A):5'-ACTTTTTCGCGAGGGACA-3'
			R (generic):TGAGGTCGGCTAGGCTGA
HGH	66	429 bp	HGH1: 5'-GCCTCCCAACCATTCCCTTA-3'
			HGH1:5'-TCACGGATTCTGTGTGTTTC-3'

The PCR reaction was carried out in a thermal cycler (Techne, UK). The cycling protocol was included in an initial denaturation at 96°C for 1min followed by 10 cycles of 15s at 96°C, 50s at 66°C, 40s at 72°C (loop 1) and was followed by 20 cycles of 10s at 96°C, 50s at 60°C and 40s at 72°C (loop 2). A total of 30 cycles was carried out with 5min at 72°C as final extension. The PCR products were electrophoresed on a 1.5% agarose gel (Merck, Germany) and stained by ethidium bromide as described previously (28). The genotyping results were tested by the presence or absence of an allele-specific PCR product, which refers to amplification of DNA sequence variants or specific alleles at the same locus. To distinguish between the two alleles, three primers were designed, the generic forward primer, the 3'-A primer and the 3'-G primer. Each allele was identified according to its size (29).

3.3. Statistical Analysis

For Hardy-Weinberg equilibrium, genotype frequencies were evaluated. By using Pearson's chi-square test and/or Fisher's exact test, the genotype frequency between HBS-Ag positive cases and control groups was compared. The risk affiliated with genotypes/alleles was assessed as the odds ratio (OR) of 95% confidence intervals (CI). All statistical analysis was done with the Statistical Program for Social Sciences (SPSS version 17.0) software. Differences were considered significant when the P value was less than 0.05.

4. Results

To determine the association of IL-13 gene polymorphisms with HBsAg positiveness, the polymorphic region of IL-13/+110 SNP was investigated in 302 HBsAg positive individuals and 283 control subjects. The distribution of genotypes and allele frequencies of the IL-13/+110 SNP in the case and the control groups are shown in Table 2. The frequencies of A/G genotype (CI = 1.18 - 2.34, OR = 1.66, P = 0.004) and A/A genotype (CI = 0.95 - 3.53, OR = 1.84, P = 0.071) were higher in the patients. As well, the A allele frequency was significantly higher in the patients than the control group (CI = 1.09 - 1.79, OR = 1.84, P = 0.071). However, the present study showed an association between the IL-13/+110 gene polymorphism and HBV.

In addition, the frequency of AA/AG/GG genotype in this polymorphic region of IL-13 was investigated in both men and women without considering their health condition (patient or healthy). These results were shown in Table 3. In general analysis, A/G genotype frequency was more prevalent in men and A/A genotype frequency was more common in women while G/G genotype frequency was approximately equal in both sexes. The association analysis of gender subgroups with HBV disease showed most of the subjects were male (Table 4). Statistical analysis showed a significant association between IL-13/+110 gene polymorphism and HBV.

5. Discussion

Hepatitis B virus infection is endemic, especially in developing countries that can cause serious liver diseases like hepatocellular cancer, cirrhosis, and chronic hepatitis. Several factors such as host-related factors (e.g. genetic and immunological history), pathogen-related factors (e.g. genotype and viral load), and environmental factors (e.g. nutrition, hygiene, vaccination, and treatment) (30) affect the consequence of HBV infection (31-36). Lots of evidence strongly report that host genetic factors (37, 38) may play a significant role in the occurrence of HBV (39) and are therefore widely studied for the various outcomes of HBV infection (16). Hepatitis B surface antigen positivity is more prevalent in identical twins than in fraternal twins (38) indicating that host-related genetic factors will impact on the cycle of HBV infection. Gene polymorphisms can affect the amino acid sequence and alter protein structure and biological function. The attendance of these inherited gene polymorphisms may make a person more resistant or susceptible to a specified disease (36, 40).

The variation in host immune response may be one of the causes of the different clinical representations of HBV infection. Polymorphisms of genes encoding the pro-inflammatory and anti-inflammatory cytokines can affect

the infection clinical demonstration. To determine high-risk people for developing chronic hepatitis, the genomic information concerning cytokines and other mediators can be significant and used to plan preventive approaches and treatment for these cases.

Cytokines represent a substantial role in initiating and maintaining a suitable immune and inflammatory response of HBV infection through direct or indirect inhibition of viral replication (15, 41-46). Therefore, several recent studies have paid attention to the effect of gene polymorphisms of cytokines on infectious disease outcome, response to vaccination and treatment. Polymorphisms in genes encoding cytokines may be the primary cause of clinical differences between patients; hence they can be used for the identification of individuals who are at high risk of developing hepatocellular carcinoma and chronic hepatitis (3, 36). So far, we have evaluated the association of several genes with hepatitis and cancer (27, 47-51).

Results of 14 studies of other authors has shown that the rate of HBsAg positive prevalence among 7 provinces of Iran (Golestan, Tehran, East Azarbaijan, Hamedan, Isfahan, Kermanshah, and Hormozgan) is different and the highest prevalence was reported in Golestan (6.3 percent; 95% CI 3.2 - 9.3 percent) (44, 46). Therefore, consideration of risk factors in this province is very important to control the disease. To date, many epidemiological studies have been performed to assess whether polymorphisms in IL-13 are involved in an individual's susceptibility to cancer. For example, association of decreased risk of glioma with IL-13 rs1800925 polymorphism (52) and IL-13 rs20541 GA and AA variant genotypes (53) were reported. As well as studies showing that cases harboring the IL-13 rs20541 T allele had a reduced risk of colorectal cancer (54) and Chinese tobacco smokers carrying the IL-13 rs1800925 CT variant genotype had 2.57-fold increased risk of bladder cancer (55).

Study of Deng *et al.* was the first one documenting the relationship between IL-13 genetic variants and hepatitis B virus-related (HBV) hepatocellular carcinoma (HCC). Their study indicated that the functional IL-13 rs20541 polymorphism may contribute to the risk of HCC (56). The human IL-13 gene located on chromosome 5q31 and has effects on immune cells so in this large case-control study, the region of the IL-13 gene position +110 was analyzed via SSP-PCR and gel electrophoresis methods. Amongst the various molecular techniques usually utilized, sequence-specific primer-PCR (PCR-SSP) method is performed as a comparatively easier and cost-effective one. Due to the primers' specificity due to a 3' single-base mismatch, this method prevents the priming of a non-specific reaction.

This study showed that the A allele and A/A genotype at the IL-13/+110 position had higher distribution among Iranian HBV patients (36.7% and 8.6% respectively) in com-

Table 2. Allele and Genotype Frequencies of IL-13/+110 in HBV and Healthy Subjects^a

IL-13 Polymorphism	Controls	Patients	OR	95% CI	P Value
Allele					
A	166 (29.3)	222 (36.7)	1.40	1.09 - 1.79	0.007
G	400 (70.6)	382 (63.2)	1	-	-
Genotype					
A/A	18 (6.4)	26 (8.6)	1.84	0.95 - 3.53	0.071
A/G	130 (45.9)	170 (56.3)	1.66	1.18 - 2.34	0.004
G/G	135 (47.7)	106 (35.1)	1	-	-
Model of inheritance					
Recessive (AA vs. AG + GG)			1.38	0.74 - 2.58	0.34
Dominant (AG + AA vs. GG)			0.59	0.42 - 0.82	0.002
Co-dominant (AG vs. AA + GG)			1.51	1.09 - 2.10	0.013

Abbreviations: OR, odds ratio; CI, confidence interval.

^aValues are expressed as No. (%).

Table 3. Genotype Frequencies of IL-13/+110 in Men and Women^a

IL-13 Polymorphism	Men, N = 333	Women, N = 157
Genotype		
A/A	26 (7.8)	16 (10.2)
A/G	165 (49.5)	75 (47.8)
G/G	142 (42.6)	66 (42)

^aValues are expressed as No. (%).

Table 4. The Association Analysis of Gender Subgroups with HBV Disease

Gender	Patients ^a	Control ^a	OR	95% CI	P Value
Female	56 (21.7)	317 (63.1)	1	-	-
Male	201 (78.2)	185 (36.8)	6.15	4.34 - 8.70	< 0.0001

^aValues are expressed as No. (%).

parison to controls (9.3% and 6.4 % respectively). In conclusion, these results suggested that the IL-13 A allele is strongly associated with susceptibility to HBV infection. On the other hand, given the high frequency of G allele in healthy individuals, suggesting that this allele has a protective role in this disease. Nevertheless, our study provides evidence that IL-13/+110 polymorphism may contribute to the risk of HBV, it may vary in different Iranian populations with the divergent genetic background. Taken together, future studies on different ethnic populations and other polymorphic regions in this cytokine gene would provide a more detailed definition for the contribution of IL-13 polymorphisms in the development of HBV disease.

5.1. Conclusions

The polymorphic region of IL-13/+110 was analyzed using SSP-PCR. The results showed that A/A frequency was higher in patients than control subjects. This suggested that A/A genotype probably plays a role in augmenting of susceptibility to HBV infection risk. In addition, a high frequency of G allele in control and healthy cases, suggests that this allele has a protective role against this disease.

Acknowledgments

We would like to thank research council of Golestan University of Medical Sciences for funding and special thanks go to all the subjects who participated in this study.

Footnotes

Authors' Contribution: Majid Shahbazi initiated the research program. Maryam Zangi genotyped the patients and controls. Azam Bakhshandeh and Majid Shahbazi accumulated and banked all of the DNA samples. Majid Shahbazi carried out the statistical analyses. Majid Shahbazi supervised the project. Maryam Zangi, Azam Bakhshandeh and Masoumeh Mehrpouya wrote the paper.

Conflict of Interests: The authors declare that there is no conflict of interests.

Ethical Approval: The project and data collection were approved by the Ethics Committee of Golestan University of Medical Sciences (#31078693122412).

Financial Disclosure: It is not declared by the authors.

Funding/Support: This work was supported by research council of Golestan University of Medical Sciences under grant number: 931212267.

Patient Consent: Written consent was received from all participants (patients and controls).

References

- Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. *J Gen Virol*. 2002;**83**(Pt 6):1267–80. doi: [10.1099/0022-1317-83-6-1267](https://doi.org/10.1099/0022-1317-83-6-1267). [PubMed: [12029141](https://pubmed.ncbi.nlm.nih.gov/12029141/)].
- Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ. Genetic variation of hepatitis B virus and its significance for pathogenesis. *World J Gastroenterol*. 2016;**22**(1):126–44. doi: [10.3748/wjg.v22.i1.126](https://doi.org/10.3748/wjg.v22.i1.126). [PubMed: [26755865](https://pubmed.ncbi.nlm.nih.gov/26755865/)]. [PubMed Central: [PMC4698480](https://pubmed.ncbi.nlm.nih.gov/PMC4698480/)].
- Behelgard A, Hosseini SM, Mohebbi SR, Azimzadeh P, Derakhshani S, Karimi K, et al. a study on genetic association of interleukin-16 single nucleotide polymorphism (rs1131445) with chronic hepatitis B virus infection in Iranian patients. *Jundishapur J Microbiol*. 2015;**8**(11). e23411. doi: [10.5812/jjm.23411](https://doi.org/10.5812/jjm.23411). [PubMed: [26855736](https://pubmed.ncbi.nlm.nih.gov/26855736/)]. [PubMed Central: [PMC4735834](https://pubmed.ncbi.nlm.nih.gov/PMC4735834/)].
- Ayub A, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level. *Biomed Res Int*. 2013;**2013**:810461. doi: [10.1155/2013/810461](https://doi.org/10.1155/2013/810461). [PubMed: [23991421](https://pubmed.ncbi.nlm.nih.gov/23991421/)]. [PubMed Central: [PMC3749539](https://pubmed.ncbi.nlm.nih.gov/PMC3749539/)].
- Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. *Lancet*. 1989;**2**(8670):1006–8. doi: [10.1016/S0140-6736\(89\)91016-7](https://doi.org/10.1016/S0140-6736(89)91016-7). [PubMed: [2572740](https://pubmed.ncbi.nlm.nih.gov/2572740/)].
- Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. *Saudi Med J*. 2005;**26**(6):974–7. [PubMed: [15983686](https://pubmed.ncbi.nlm.nih.gov/15983686/)].
- Milani S, Sharifi Z, Hosseini M, Shoostari MM. Determination of HBV genotypes among HBs Ag positive blood donors in Tehran, Iran using PCR-RFLP. *Iran J Publ Health*. 2009;**38**(1):41–7.
- Poustchi H, Mohammadkhani A, Bowden S, Montazeri G, Ayres A, Revill P, et al. Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease. *J Viral Hepat*. 2008;**15**(10):753–60. doi: [10.1111/j.1365-2893.2008.00998.x](https://doi.org/10.1111/j.1365-2893.2008.00998.x). [PubMed: [18507754](https://pubmed.ncbi.nlm.nih.gov/18507754/)].
- Alavian SM, Keyvani H, Rezaei M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. *World J Gastroenterol*. 2006;**12**(32):5211–3. [PubMed: [16937535](https://pubmed.ncbi.nlm.nih.gov/16937535/)]. [PubMed Central: [PMC4088022](https://pubmed.ncbi.nlm.nih.gov/PMC4088022/)].
- Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human immunodeficiency virus infections in Hamadan province, Iran: A population based study. *J Trop Med Hyg*. 1993;**96**(5):277–87. [PubMed: [8411302](https://pubmed.ncbi.nlm.nih.gov/8411302/)].
- Romani S, Hosseini SM, Mohebbi SR, Kazemian S, Derakhshani S, Khanyaghma M, et al. Interleukin-16 gene polymorphisms are considerable host genetic factors for patients' susceptibility to chronic hepatitis B infection. *Hepat Res Treat*. 2014;**2014**:790753. doi: [10.1155/2014/790753](https://doi.org/10.1155/2014/790753). [PubMed: [25692036](https://pubmed.ncbi.nlm.nih.gov/25692036/)]. [PubMed Central: [PMC4322659](https://pubmed.ncbi.nlm.nih.gov/PMC4322659/)].
- Pujol FH, Navas MC, Hainaut P, Chemin I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. *Cancer Lett*. 2009;**286**(1):80–8. doi: [10.1016/j.canlet.2009.07.013](https://doi.org/10.1016/j.canlet.2009.07.013). [PubMed: [19683385](https://pubmed.ncbi.nlm.nih.gov/19683385/)].
- Krugman S, Overby LR, Mushahwar IK, Ling CM, Frosner GG, Deinhardt F. Viral hepatitis, type B. Studies on natural history and prevention re-examined. *N Engl J Med*. 1979;**300**(3):101–6. doi: [10.1056/NEJM197901183000301](https://doi.org/10.1056/NEJM197901183000301). [PubMed: [758598](https://pubmed.ncbi.nlm.nih.gov/758598/)].
- Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. *Semin Liver Dis*. 1991;**11**(2):73–83. doi: [10.1055/s-2008-1040426](https://doi.org/10.1055/s-2008-1040426). [PubMed: [1909458](https://pubmed.ncbi.nlm.nih.gov/1909458/)].
- Khanizadeh S, Ravanshad M, Mohebbi S, Naghoosi H, Mousavinasab S, Romnani S, et al. Correlation between Polymorphism of-56 SNP (T/C) Interferon- γ Receptor 1 Gene and Chronic HBV Infection. *Iran J virol*. 2011;**5**(2):19–24. doi: [10.21859/ijsv.5.2.19](https://doi.org/10.21859/ijsv.5.2.19).
- Zhu XL, Du T, Li JH, Lu LP, Guo XH, Gao JR, et al. Association of HLA-DQB1 gene polymorphisms with outcomes of HBV infection in Chinese Han population. *Swiss Med Wkly*. 2007;**137**(7-8):114–20. [PubMed: [17370149](https://pubmed.ncbi.nlm.nih.gov/17370149/)].
- Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, et al. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. *World J Gastroenterol*. 2009;**15**(44):5610–9. doi: [10.3748/wjg.15.5610](https://doi.org/10.3748/wjg.15.5610). [PubMed: [19938203](https://pubmed.ncbi.nlm.nih.gov/19938203/)]. [PubMed Central: [PMC2785066](https://pubmed.ncbi.nlm.nih.gov/PMC2785066/)].
- Conde SR, Feitosa RN, Freitas FB, Hermes RB, Demachki S, Araujo MT, et al. Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B. *Cytokine*. 2013;**61**(3):940–4. doi: [10.1016/j.cyto.2013.01.004](https://doi.org/10.1016/j.cyto.2013.01.004). [PubMed: [23395388](https://pubmed.ncbi.nlm.nih.gov/23395388/)].
- Korachi M, Ceran N, Adaleti R, Nigdelioglu A, Sokmen M. An association study of functional polymorphic genes IRF-1, IFNGR-1, and IFN-gamma with disease progression, aspartate aminotransferase, alanine aminotransferase, and viral load in chronic hepatitis B and C. *Int J Infect Dis*. 2013;**17**(1):e44–9. doi: [10.1016/j.ijid.2012.08.004](https://doi.org/10.1016/j.ijid.2012.08.004). [PubMed: [23040881](https://pubmed.ncbi.nlm.nih.gov/23040881/)].
- Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. *J Immunol*. 2008;**181**(7):4656–65. doi: [10.4049/jimmunol.181.7.4656](https://doi.org/10.4049/jimmunol.181.7.4656). [PubMed: [18802068](https://pubmed.ncbi.nlm.nih.gov/18802068/)].
- Hussein YM, Ahmad AS, Ibrahim MM, Elsherbeny HM, Shalaby SM, El-Shal AS, et al. Interleukin 13 receptors as biochemical markers in atopic patients. *J Investig Allergol Clin Immunol*. 2011;**21**(2):101–7. [PubMed: [21462799](https://pubmed.ncbi.nlm.nih.gov/21462799/)].
- Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. *Gut*. 2012;**61**(12):1765–73. doi: [10.1136/gutjnl-2012-303461](https://doi.org/10.1136/gutjnl-2012-303461). [PubMed: [22942239](https://pubmed.ncbi.nlm.nih.gov/22942239/)].
- Junttila IS, Mizukami K, Dickensheets H, Meier-Schellersheim M, Yamane H, Donnelly RP, et al. Tuning sensitivity to IL-4 and IL-13: Differential expression of IL-4R α , IL-13R α 1, and γ chain regulates relative cytokine sensitivity. *J Exp Med*. 2008;**205**(11):2595–608. doi: [10.1084/jem.20080452](https://doi.org/10.1084/jem.20080452). [PubMed: [18852293](https://pubmed.ncbi.nlm.nih.gov/18852293/)]. [PubMed Central: [PMC2571934](https://pubmed.ncbi.nlm.nih.gov/PMC2571934/)].
- Seyfzadeh N, Seyfzadeh N, Gharibi T, Babaloo Z. Interleukin-13 as an important cytokine: A review on its roles in some human diseases. *Acta Microbiol Immunol Hung*. 2015;**62**(4):341–78. doi: [10.1556/030.62.2015.4.2](https://doi.org/10.1556/030.62.2015.4.2). [PubMed: [26689873](https://pubmed.ncbi.nlm.nih.gov/26689873/)].
- McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol*. 2001;**50**(1):121–7. doi: [10.1002/ana.1032](https://doi.org/10.1002/ana.1032). [PubMed: [11456302](https://pubmed.ncbi.nlm.nih.gov/11456302/)].
- Zamani M, Mehri M, Kollaee A, Yenki P, Ghaffarpour M, Harirchian MH, et al. Pharmacogenetic study on the effect of rivastigmine on PS2 and APOE genes in Iranian Alzheimer patients. *Dement Geriatr Cogn Dis Extra*. 2011;**1**(1):180–9. doi: [10.1159/000329514](https://doi.org/10.1159/000329514). [PubMed: [22163243](https://pubmed.ncbi.nlm.nih.gov/22163243/)]. [PubMed Central: [PMC3199882](https://pubmed.ncbi.nlm.nih.gov/PMC3199882/)].
- Mansoori M, Golalipour M, Alizadeh S, Jahangirerad A, Khandozi SR, Fakharai H, et al. Genetic variation in the ABCB1 gene may lead to mRNA level change: Application to gastric cancer cases. *Asian Pac J Cancer Prev*. 2015;**16**(18):8467–71. doi: [10.7314/APJCP.2015.16.18.8467](https://doi.org/10.7314/APJCP.2015.16.18.8467). [PubMed: [26745103](https://pubmed.ncbi.nlm.nih.gov/26745103/)].
- Haghighi A, Fathi D, Shahbazi M, Motahari MM, Friedman B. Identification of a c.601C>G mutation in the CCM1 gene in a kindred with multiple skin, spinal and cerebral cavernous malformations. *J Neurol Sci*. 2013;**334**(1-2):97–101. doi: [10.1016/j.jns.2013.07.2518](https://doi.org/10.1016/j.jns.2013.07.2518). [PubMed: [24007869](https://pubmed.ncbi.nlm.nih.gov/24007869/)].
- Ugozzoli L, Wallace RB. Allele-specific polymerase chain reaction. *Methods*. 1991;**2**(1):42–8. doi: [10.1016/S1046-2023\(05\)80124-0](https://doi.org/10.1016/S1046-2023(05)80124-0).

30. Thursz M. Genetic susceptibility in infectious diseases. *Biotechnol Genet Eng Rev*. 2000;**17**:253-64. doi: [10.1080/02648725.2000.10647994](https://doi.org/10.1080/02648725.2000.10647994). [PubMed: [11255668](https://pubmed.ncbi.nlm.nih.gov/11255668/)].
31. Grunhage F, Nattermann J. Viral hepatitis: Human genes that limit infection. *Best Pract Res Clin Gastroenterol*. 2010;**24**(5):709-23. doi: [10.1016/j.bpg.2010.07.009](https://doi.org/10.1016/j.bpg.2010.07.009). [PubMed: [20955972](https://pubmed.ncbi.nlm.nih.gov/20955972/)].
32. Mackay IR. Genetic susceptibility to chronic hepatitis B virus infection. *J Gastroenterol Hepatol*. 2006;**21**(7):1087-8. doi: [10.1111/j.1440-1746.2006.04430.x](https://doi.org/10.1111/j.1440-1746.2006.04430.x). [PubMed: [16824056](https://pubmed.ncbi.nlm.nih.gov/16824056/)].
33. McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL. Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. *Annu Rev Public Health*. 2000;**21**:15-46. doi: [10.1146/annurev.publhealth.21.1.15](https://doi.org/10.1146/annurev.publhealth.21.1.15). [PubMed: [10884944](https://pubmed.ncbi.nlm.nih.gov/10884944/)].
34. Thursz MR. Host genetic factors influencing the outcome of hepatitis. *J Viral Hepat*. 1997;**4**(4):215-20. doi: [10.1046/j.1365-2893.1997.00052.x](https://doi.org/10.1046/j.1365-2893.1997.00052.x). [PubMed: [9278218](https://pubmed.ncbi.nlm.nih.gov/9278218/)].
35. Thursz M, Yee L, Khakoo S. Understanding the host genetics of chronic hepatitis B and C. *Semin Liver Dis*. 2011;**31**(2):115-27. doi: [10.1055/s-0031-1276642](https://doi.org/10.1055/s-0031-1276642). [PubMed: [21538279](https://pubmed.ncbi.nlm.nih.gov/21538279/)].
36. Tuncbilek S. Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection. *World J Gastroenterol*. 2014;**20**(20):6226-35. doi: [10.3748/wjg.v20.i20.6226](https://doi.org/10.3748/wjg.v20.i20.6226). [PubMed: [24876743](https://pubmed.ncbi.nlm.nih.gov/24876743/)]. [PubMed Central: [PMC4033460](https://pubmed.ncbi.nlm.nih.gov/PMC4033460/)].
37. Thursz M. Genetic susceptibility in chronic viral hepatitis. *Antiviral Res*. 2001;**52**(2):113-6. doi: [10.1016/S0166-3542\(01\)00175-9](https://doi.org/10.1016/S0166-3542(01)00175-9). [PubMed: [11672820](https://pubmed.ncbi.nlm.nih.gov/11672820/)].
38. Lin TM, Chen CJ, Wu MM, Yang CS, Chen JS, Lin CC, et al. Hepatitis B virus markers in Chinese twins. *Anticancer Res*. 1989;**9**(3):737-41. [PubMed: [2764519](https://pubmed.ncbi.nlm.nih.gov/2764519/)].
39. Wang L, Wu XP, Zhang W, Zhu DH, Wang Y, Li YP, et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: Two independent case-control studies. *PLoS One*. 2011;**6**(3). e17608. doi: [10.1371/journal.pone.0017608](https://doi.org/10.1371/journal.pone.0017608). [PubMed: [21408128](https://pubmed.ncbi.nlm.nih.gov/21408128/)]. [PubMed Central: [PMC3050917](https://pubmed.ncbi.nlm.nih.gov/PMC3050917/)].
40. de Andrade DR Jr, de Andrade DR. The influence of the human genome on chronic viral hepatitis outcome. *Rev Inst Med Trop Sao Paulo*. 2004;**46**(3):119-26. doi: [10.1590/S0036-46652004000300001](https://doi.org/10.1590/S0036-46652004000300001). [PubMed: [15286811](https://pubmed.ncbi.nlm.nih.gov/15286811/)].
41. Borzooy Z, Streinu-Cercel A, Mirshafiey A, Khamseh A, Mahmoudie MK, Navabi SS, et al. IL-17 and IL-22 genetic polymorphisms in HBV vaccine non- and low-responders among healthcare workers. *Germes*. 2016;**6**(1):14-20. doi: [10.11599/germes.2016.1084](https://doi.org/10.11599/germes.2016.1084). [PubMed: [27019828](https://pubmed.ncbi.nlm.nih.gov/27019828/)]. [PubMed Central: [PMC4788777](https://pubmed.ncbi.nlm.nih.gov/PMC4788777/)].
42. Sun Y, Lu Y, Xie L, Deng Y, Li S, Qin X. Interferon gamma polymorphisms and hepatitis B virus-related liver cirrhosis risk in a Chinese population. *Cancer Cell Int*. 2015;**15**:35. doi: [10.1186/s12935-015-0184-2](https://doi.org/10.1186/s12935-015-0184-2). [PubMed: [25861244](https://pubmed.ncbi.nlm.nih.gov/25861244/)]. [PubMed Central: [PMC4389711](https://pubmed.ncbi.nlm.nih.gov/PMC4389711/)].
43. de Oliveira LC, Goldberg AC, Marin ML, Schneidwind KR, Frade AF, Kalil J, et al. Autoimmune hepatitis in Brazilian children: IgE and genetic polymorphisms in associated genes. *J Immunol Res*. 2015;**2015**:679813. doi: [10.1155/2015/679813](https://doi.org/10.1155/2015/679813). [PubMed: [26693492](https://pubmed.ncbi.nlm.nih.gov/26693492/)]. [PubMed Central: [PMC4674601](https://pubmed.ncbi.nlm.nih.gov/PMC4674601/)].
44. Chakravarty R. Host genetic factors in hepatitis B virus infection. *Int J Hum Genetics*. 2005;**5**(1):33-6. doi: [10.1080/09723757.2005.11885913](https://doi.org/10.1080/09723757.2005.11885913).
45. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Daneshmandi S, Shamsizadeh A, et al. Non-association of IL-12 +1188 and IFN-gamma +874 polymorphisms with cytokines serum level in occult HBV infected patients. *Saudi J Gastroenterol*. 2011;**17**(1):30-5. doi: [10.4103/1319-3767.74461](https://doi.org/10.4103/1319-3767.74461). [PubMed: [21196650](https://pubmed.ncbi.nlm.nih.gov/21196650/)]. [PubMed Central: [PMC3099077](https://pubmed.ncbi.nlm.nih.gov/PMC3099077/)].
46. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, Kabir A, Bagheri-Lankarani K. Hepatitis B Virus infection in Iran: A systematic review. *Hepat Mon*. 2008;**8**(4):281-94.
47. Abdolmohammadi R, Shahbazi Azar S, Khosravi A, Shahbazi M. CCR5 polymorphism as a protective factor for hepatocellular carcinoma in hepatitis B virus-infected Iranian patients. *Asian Pac J Cancer Prev*. 2016;**17**(10):4643-6. [PubMed: [27892677](https://pubmed.ncbi.nlm.nih.gov/27892677/)]. [PubMed Central: [PMC5454610](https://pubmed.ncbi.nlm.nih.gov/PMC5454610/)].
48. Attar M, Azar SS, Shahbazi M. Interleukin-6/174 promoter polymorphism and susceptibility to hepatitis B virus infection as a risk factor for hepatocellular carcinoma via hepatitis B infection. *Asian Pac J Cancer Prev*. 2016;**17**(5):2395-9. [PubMed: [27268603](https://pubmed.ncbi.nlm.nih.gov/27268603/)].
49. Azar SS, Mansoori M, Attar M, Shahbazi M. Tumor necrosis factor alpha 308 G/A single nucleotide polymorphism and susceptibility to hepatocellular carcinoma via hepatitis B infection. *Asian Pac J Cancer Prev*. 2016;**17**(7):3381-4. [PubMed: [27509979](https://pubmed.ncbi.nlm.nih.gov/27509979/)].
50. Ghasemian R, Babamahmoodi F, Ahangarkani F. Hepatitis A is a health hazard for iranian pilgrims who go to Holly Karbala: A preliminary report. *Hepat Mon*. 2016;**16**(6). e38138. doi: [10.5812/hepatmon.38138](https://doi.org/10.5812/hepatmon.38138). [PubMed: [27630729](https://pubmed.ncbi.nlm.nih.gov/27630729/)]. [PubMed Central: [PMC5011296](https://pubmed.ncbi.nlm.nih.gov/PMC5011296/)].
51. Ghasemian N, Shahbazi M. Interferon gamma gene polymorphism (+874 T > A) and chronic hepatitis B in the population of Gorgan, North-Eastern Iran. *Jundishapur J Microbiol*. 2016;**9**(8). e33639. doi: [10.5812/jjm.33639](https://doi.org/10.5812/jjm.33639). [PubMed: [27800132](https://pubmed.ncbi.nlm.nih.gov/27800132/)]. [PubMed Central: [PMC5080914](https://pubmed.ncbi.nlm.nih.gov/PMC5080914/)].
52. Su T, Mi Y, Zhang L, Wang S, Lu H, Shi L, et al. Association between IL13 gene polymorphisms and susceptibility to cancer: A meta-analysis. *Gene*. 2013;**515**(1):56-61. doi: [10.1016/j.gene.2012.11.035](https://doi.org/10.1016/j.gene.2012.11.035). [PubMed: [23246181](https://pubmed.ncbi.nlm.nih.gov/23246181/)].
53. Sun G, Wang X, Shi L, Yue X, Fu L, Chen C, et al. Association between polymorphisms in interleukin-4Ralpha and interleukin-13 and glioma risk: A meta-analysis. *Cancer Epidemiol*. 2013;**37**(3):306-10. doi: [10.1016/j.canep.2013.01.003](https://doi.org/10.1016/j.canep.2013.01.003). [PubMed: [23395224](https://pubmed.ncbi.nlm.nih.gov/23395224/)].
54. Sainz J, Rudolph A, Hoffmeister M, Frank B, Brenner H, Chang-Claude J, et al. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. *J Clin Endocrinol Metab*. 2012;**97**(5):E845-51. doi: [10.1210/jc.2011-2565](https://doi.org/10.1210/jc.2011-2565). [PubMed: [22419714](https://pubmed.ncbi.nlm.nih.gov/22419714/)].
55. Chu H, Ma L, Wang M, Shi D, Qin C, Yuan L, et al. The polymorphisms of IL-4, IL-4R and IL-13 genes and bladder cancer risk in a Chinese population: A case-control study. *Mol Biol Rep*. 2012;**39**(5):5349-57. doi: [10.1007/s11033-011-1334-9](https://doi.org/10.1007/s11033-011-1334-9). [PubMed: [22170601](https://pubmed.ncbi.nlm.nih.gov/22170601/)].
56. Deng Y, Xie M, Xie L, Wang J, Li T, He Y, et al. Association between polymorphism of the interleukin-13 gene and susceptibility to hepatocellular carcinoma in the Chinese population. *PLoS One*. 2015;**10**(2). e0116682. doi: [10.1371/journal.pone.0116682](https://doi.org/10.1371/journal.pone.0116682). [PubMed: [25658755](https://pubmed.ncbi.nlm.nih.gov/25658755/)]. [PubMed Central: [PMC4319784](https://pubmed.ncbi.nlm.nih.gov/PMC4319784/)].